Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515660-31-00

Enrollment

Registered

2024-10-24

Start date

2023-06-27

Completion date

2026-01-12

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intrahepatic cholangiocarcinoma

Brief summary

R0/R1-resection rates

Detailed description

Pathological response rates, radiological resectability and response, safety and toxicity, 90-day perioperative morbidity, mortality and QoL

Interventions

DRUGGEMCITABINE HYDROCHLORIDE

DRUGCISPLATIN

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGIMJUDO 20 mg/ml concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
R0/R1-resection rates	—

Secondary

Measure	Time frame
Pathological response rates, radiological resectability and response, safety and toxicity, 90-day perioperative morbidity, mortality and QoL	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026